摘要
凝血因子ⅤⅢ制剂是治疗血友病甲的最主要血液制品。８０年代中期发展了新一代血浆凝血因子ⅤⅢ浓制剂及基因重组凝血因子ⅤⅢ技术，不仅提高了凝血因子ⅤⅢ制剂的纯度，减少了副作用，而且降低了病毒感染的危险性。本文介绍凝血因子ⅤⅢ制剂的生产及病毒灭活工艺。
Factor Ⅷ is an essential cofactor for normal hemostatic function.It is evident that FⅧ concentrate increases promptly the activity of FⅧ in vivo and arrestes bleeding for persons with hemophilia A (FⅧ deficiency).In the mid 80′s,new generations of plasma derived FⅧ concentrate with high purity and viral safety were developed.This review will focus on the methods of virus inactivation and the current status of FⅧ preparations from plasma or by recombinant DNA technique.
出处
《药学进展》
CAS
1997年第1期26-30,共5页
Progress in Pharmaceutical Sciences
关键词
凝血因子Ⅷ
制备工艺
重组
病毒灭活
Coagulation Factor Ⅷ Manufacturing technology Recombinant Riral inactivation
